Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Feb 5, 2025--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement.
Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
About ADI-001
ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), and SLE with extrarenal involvement. The Company is advancing ADI-001 across six autoimmune indications. Patient enrollment is ongoing in the Phase 1 study evaluating ADI-001 for the treatment of LN. Patient enrollment in SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM, or myositis), and stiff person syndrome (SPS) is expected to be initiated in the first quarter of 2025. Initiation of enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is expected in the second half of 2025. In the Phase 1 GLEAN trial, ADI-001 was shown to target B-cells via an anti-CD20 CAR and demonstrated robust exposure and complete CD19+ B-cell depletion both in peripheral blood and secondary lymphoid tissue.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding the initiation of patient enrollment for the Phase 1 trial of ADI-001 in SLE, SSc, IIM, SPS and ANCA AAV and potential benefits resulting from the Fast Track Designation.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global geopolitical conflicts and economic conditions on Adicet's business and financial results, including with respect to disruptions to Adicet's preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet's ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Adicet's most recent annual report on Form 10-K and periodic and current reports on Form 10-Q and Form 8-K filed with the U.S. Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet's other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.
CONTACT: Adicet Bio, Inc.
Investor and Media ContactsInvestors:
Anne Bowdidge
[email protected] Mohite
Precision AQ
212-362-1200
[email protected]:
Kerry Beth Daly
[email protected]
INDUSTRY KEYWORD: ONCOLOGY HEALTH FDA STEM CELLS GENETICS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Adicet Bio, Inc.
Copyright Business Wire 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Salmonella outbreak in cucumbers expands to 18 states, 45 sickened
A salmonella outbreak traced to a Florida-based cucumber producer has expanded to include 45 people reporting illness in 18 states, the U.S. Food and Drug Administration said Friday. Target stores joined a growing list of retailers that sold recalled cucumbers or ready-to-eat products featuring the fruit, and it's warning that purchasers should throw them away. The retailer issued a list of recalled products, including a Greek-style chicken salad from Boar's Head and several types of sushi restaurant staples, such as maki rolls with tempura and California rolls, all sold under the Mai brand. Last week, grocery store chain Walmart was added to the list of retailers urging customers to put the possibly tainted products in the trash, according to the U.S. Food and Drug Administration; its Marketside cucumber slices are a part of the recall. Patients connected to the outbreak have turned up in Alabama, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Massachusetts, Michigan, North Carolina, New York, Ohio, Pennsylvania, South Carolina, Tennessee and Virginia, the FDA said on Friday. Of 45 people who have reported illness connected to the outbreak, 16 have been hospitalized, the agency said. No deaths have been reported. While investigators' focus has been on the strain salmonella montevideo, multiple other strains were detected in samples taken from a Pennsylvania distribution center belonging to Florida-based Bedner Growers, believed to be a source, the FDA said in its Friday statement. The FDA said that those different strains so far appear to be unrelated to the spring outbreak, but that it is investigating further alongside scientists from the U.S. Centers for Disease Control and Prevention. "CDC is working to determine if additional human illnesses match these additional strains," the FDA said. "Further analysis of the sample is pending." All the illnesses so far have been connected to cucumbers produced by Bedner and distributed by Fresh Start Produce Sales, the agency said. The cucumbers and products that contained them were sold from April 29 to May 19, the FDA said. The first retailers noted for selling the potentially tainted cucumbers were three Bedner's Farm Fresh Market locations in Florida, but the list of public-facing sellers has continued to increase. Other distributors as well as eateries were told they may have also purchased the possibly tainted cucumbers, labeled for wholesale as 'supers,' 'selects,' or 'plains," the FDA said. FDA inspectors unearthed tainted cucumbers during an inspection last month of Bedner Growers' facilities, it said. The review was a follow-up to a Salmonella Africana outbreak linked to the producer last year, according to the agency. Bedner's did not immediately respond to a request for comment late Friday. A spokesperson for Fresh Start Produce Sales said last week that the company "is committed to protecting public health and helping Bedner Growers with its recall." Salmonella is a bacterium that can thrive amid animals and their fecal matter and contaminate nearby produce, which can reach the dinner table if unwashed, according to the FDA and CDC. Older people, children under 5, and those with compromised immune systems are particularly susceptible to the salmonella's worst symptoms and even death. Patients sickened by it can develop stomach cramps, diarrhea, nausea and the urge to vomit anywhere from six hours to six days after infection, the CDC says. Salmonella is 'a leading cause of foodborne illness, hospitalizations, and deaths in the United States and worldwide," the CDC states. This article was originally published on
Yahoo
18 minutes ago
- Yahoo
'Being smart on crime' leading to downtrend of overdoses
TUNKHANNOCK, WYOMING COUNTY (WBRE/WYOU)— A local community is doing its part to combat the opioid epidemic by handing out a potentially life saving drug Narcan. It's a medication that counteracts the effects of opiate related overdoses. Wyoming County District Attorney Joe Peters, along with his community awareness group, set up shop in Tunkhannock in an effort to get this potential life-saver in as many hands as possible. For years, Wyoming County has been putting up a fight against the opioid epidemic through community events like this one. DAs share crime trends in Luzerne and Lackawanna counties The anonymous drive-through event hopes get Narcan in the hands of as many residents as possible, something District Attorney Joe Peters calls being 'smart on crime'. 'We just want to get Narcan out there. It's like a fire extinguisher. There's one in every building because, you're not trying to encourage a fire, you're trying to have something there to stop the fire,' said District Attorney Peters. Inside the kits, Narcan and instructions on how to administer it. Narcan is a nasal form of the drug naloxone. It binds with opioid receptors in the brain to reverse the effects of an overdose. The drug is not harmful to the user. 'That's the magic and the miracle of this drug,' expressed District Attorney Peters. While opioid related deaths are on the downtrend here in Wyoming County, District Attorney Joe Peters says distribution events like this one are crucial to continuing the fight against opioid abuse. One woman attending the event tells me she lost her brother to a fentanyl overdose only a few years ago. She says she wishes resources like these could have been available then. 'I think not only being aware that this, you know, is in our communities, this fentanyl, but being knowledgeable that there are things like Narcan that can make a difference,' said Mary Scarpa, Tunkhannock. She says now, she carries Narcan wherever she goes just in case someone needs it. 'If the situation ever occurs that, you know, I can help somebody out then I certainly would like to. It is really difficult to lose somebody to an overdose and so I don't wish that upon anybody,' expressed Scarpa. Peters says he hopes to have more Narcan distribution events throughout Wyoming County in the future. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
24 minutes ago
- Yahoo
Food and fitness make or break success on weight loss meds, report finds
Drugs like Wegovy and Zepbound -- GLP-1 medications typically used to treat obesity -- can lead to impressive weight loss. But a new joint advisory from four major medical groups warns that without proper nutrition and lifestyle support, people may face muscle loss, weight regain, and high long-term costs once they take themselves off GLP-1 medications. Experts from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society contributed to the report, which noted that only about half of users continue taking their GLP-1 medication after one year and only about 15% remain on treatment after two years. Many people stop taking GLP-1 medications due to side effects, cost or disappointing results -- and when they do, they often regain weight, making long-term success depend on consistent use and a healthy diet, the report stated. The report aims to guide both clinicians and patients on nutrition and lifestyle changes to improve long-term outcomes while taking a GLP-1. "We really wanted to bring in four major societies together that focus on nutrition, lifestyle, [and] obesity and come with a consensus statement on how nutrition should be thought about when prescribing these drugs," Dr. Dariush Mozaffarian, a cardiologist, director of the Food is Medicine Institute at Tufts University, and the report's lead author, told ABC News. Mozaffarian explained that for someone to achieve success on a GLP-1, they need to commit to comprehensive lifestyle changes. "The FDA says these drugs are approved for use as an adjunct to lifestyle therapy," he said. "In fact, they are prescribed the other way around with lifestyle therapy being the adjunct if being thought about at all. Doctors are not following either society guidelines or FDA guidelines if they are prescribing [GLP-1s] without lifestyle therapy." Understanding diet, nutritional needs while on weight loss drugs Before starting GLP-1 medications, the report recommended that patients work with their doctors to set goals that focus on overall health, not just weight loss. It's also important to check for any stomach or bone issues that could lead to side effects like nausea, vomiting, or muscle and bone loss, the report stated. "Registered dietitians can play really key roles in comprehensive obesity care by providing medical nutrition therapy to support GLP-1 therapy," said Emily A. Callahan, registered dietitian nutritionist and director of policy strategy for the Food is Medicine Institute. "The evidence space is growing that shows when registered dietitians deliver medical nutrition therapy, it has been associated with improvements in body weight, waist circumference, blood pressure and glycemic control." People should usually start GLP-1 medications at the lowest dose and slowly increase as needed, the report said. Patients should also be aware that nausea is common when taking these drugs and this may trigger cravings for sugary, high-calorie comfort foods that work against weight loss. To stay on track, the report recommended eating small, frequent meals and focusing on minimally processed, nutrient-rich foods. The report called for exercising special caution for anyone following an intermittent fasting diet or a low-carbohydrate "keto diet" that limits foods like breads, pastas and fruit to put the body into a state called ketosis, where it burns fat for fuel instead of carbs. These individuals might be especially vulnerable to gastrointestinal side effects, the report said. The report also advised people who may not be getting enough nutrients to consider taking supplements like vitamin D, calcium and multivitamins, while increasing protein intake by 50-100% from foods such as fish, eggs, nuts and seeds. This is especially important for those eating less while on GLP-1s, since lower food intake can make it harder to get all the nutrients the body needs. The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss can also lead to muscle loss -- especially in older adults -- the report advised doing a full body strength training routine at least three times a week and getting 150 minutes of moderate cardio each week. Josh Gad opens up for 1st time about taking weight loss drug: 'It is life-changing' Focusing on nutrition, physical activity and other healthy lifestyle habits should give GLP-1 users a greater chance of achieving their goals, the report concluded. "GLP-1s have the best chance of helping people achieve and sustain lasting weight reduction when they are paired with strong nutrition guidance and lifestyle support," said Callahan. Dr. Brendan Huang serves as the chief resident physician in adult neurology at Northwell Health and is also a member of the ABC News Medical Unit. Food and fitness make or break success on weight loss meds, report finds originally appeared on
